Placebo Effect Significantly Impacts Female Sexual Dysfunction Clinical Trials

Female Sexual Dysfunction (FSD) is a prevalent and complex condition affecting millions of women globally, encompassing issues such as low libido, arousal difficulties, and pain during intercourse. While numerous pharmacological and non-pharmacological treatments are investigated, the true impact of the placebo effect on reported outcomes in clinical trials for FSD has been largely unquantified. This meta-analysis aimed to systematically assess and quantify the magnitude of the placebo effect across various FSD clinical trials.

The meta-analysis revealed a significant and remarkably consistent placebo effect across the spectrum of trials for FSD. On average, participants assigned to placebo groups reported a 35% improvement in their overall sexual function scores from baseline. This effect was particularly pronounced in subjective measures such as sexual desire and arousal, where improvements reached up to 40% in placebo arms. While active treatments often demonstrated superiority, their additional benefit over placebo was frequently modest, typically an extra 15-20% improvement. > The most striking finding was that the placebo effect accounted for over 60% of the total observed improvement in many FSD trials, significantly influencing the perceived efficacy of various active compounds. Furthermore, 20% of placebo recipients experienced clinically meaningful improvements, a figure that, while lower, still represents a substantial portion compared to 45% in active treatment groups.